

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner

Phillip Gambel

Group Art Unit :

1644

Applicants

Michael J. Yellin et al.

Application No.:

09/343,001

Confirmation No.: 7400

Filed

June 29, 1999

For

THERAPEUTIC APPLICATIONS FOR THE ANTI-T-

BAM (CD40-L) MONOCLONAL ANTIBODY 5C8 IN

THE TREATMENT OF VASCULITIS

New York, New York December 4, 2001

Hon. Commissioner for Patents Washington, D.C. 20231

## TRANSMITTAL LETTER FOR FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Transmitted herewith is a Fourth Supplemental Information Disclosure Statement in the above-identified application.

In accordance with 37 C.F.R. § 1.97, this Fourth Supplemental Information Disclosure Statement is accompanied by:

[X] a Statement as required under 37 C.F.R.

§ 1.97(e)(1) or § 1.97(e)(2);

[X] the fee as set forth in 37 C.F.R. § 1.17(p).

The Director is hereby authorized to charge payment of any additional fees required in connection with the accompanying Fourth Supplemental Information Disclosure Statement, or credit any overpayment, to Deposit Account No. 06-1075. A duplicate copy of this letter is transmitted herewith.

Respectfully submitted,

James F. Haley, Jr. (Reg. No. 27,794)

Margaret A. Pierri (Reg. No. 30,709)

Attorneys for Applicants

Shawn-Marie Mayrand (Reg. No. 48,986)

Agent for Applicants

c/o FISH & NEAVE

1251 Avenue of the Americas New York, New York 10020-1104

Tel.: (212) 596-9000 Fax: (212) 596-9090

I Hereby Certify that this Correspondence is being Deposited with the U.S. Postal Service as First Class Mail in an Envelope Addressed to: COMMISSIONER FOR PATENTS WASHINGTON, D.C. 20231 on

Hellen Baria Agnature of Person Signing.

ecember

2